How does intravenous everolimus address limits of oral everolimus?

Question

Accepted Answer

Intravenous Everolimus Formulation Addresses Limitations of Oral Administration

Sapu003, an investigational intravenous formulation of everolimus developed using Sapu Nano's Deciparticle™ nanoparticle platform, is designed to overcome the formulation challenges inherent in oral everolimus. This novel approach enables intravenous administration, supported by a scalable current good manufacturing practice (cGMP) process, thereby addressing limitations associated with the oral route. The Deciparticle™ platform itself is engineered to transform poorly water-soluble drugs into ultra-small nanoparticles suitable for intravenous delivery.
Overcoming Formulation Limitations Through Nanoparticle Technology

The development of Sapu003 specifically targets the inherent difficulties in formulating oral everolimus. By utilizing the proprietary Deciparticle™ platform, Sapu Nano has created an intravenous formulation. This platform is designed to encapsulate highly water-insoluble therapeutics, such as everolimus, into nanoparticles measuring below 20 nanometers. This nano-sizing is crucial for achieving effective intravenous administration and potentially improving drug delivery characteristics that are compromised in oral formulations.
Enhancing Drug Delivery with Amphiphilic Polymer Architectures

The Deciparticle™ platform employs amphiphilic polymer architectures as a core component of its technology. These structures are intended to enhance the compatibility of the therapeutic agent with aqueous environments, a critical factor for intravenous formulations. By improving aqueous compatibility, stability, and manufacturability, these polymer architectures facilitate a more consistent and reliable drug delivery system. This approach offers translational flexibility, suggesting potential applicability across a range of different therapeutic classes beyond everolimus.
Clinical Validation and Manufacturing Process

The progression of Sapu003 in clinical trials, specifically the SP-03-B101 Phase 1b study, provides evidence of its development pathway. The independent Safety Review Committee's recommendation to advance to the next dose level, following the observation of no dose-limiting toxicities in the initial cohort, indicates a positive safety profile for the intravenous formulation. Furthermore, the publication in the International Journal of Molecular Sciences details a stable intravenous everolimus nanoparticle formulation and highlights a scalable cGMP manufacturing process. This scalable process is essential for the clinical production and potential future commercialization of Sapu003, ensuring its availability for patient treatment.

Reading history

Hide →

This history is cleared when the page is closed.

How does intravenous everolimus address limits of oral everolimus?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends